Breaking News Instant updates and real-time market news.

FIT

Fitbit

$5.98

0.245 (4.28%)

11:25
08/08/17
08/08
11:25
08/08/17
11:25

Fitbit call volume above normal and directionally bullish

Bullish option flow detected in Fitbit with 4,585 calls trading, 1.4x expected, and implied vol increasing almost 3 points to 43.50%. 8/11 weekly 6 calls and 8/11 weekly 5.5 calls are the most active options, with total volume in those strikes near 1,100 contracts. The Put/Call Ratio is 0.18. Earnings are expected on November 1st.

FIT Fitbit
$5.98

0.245 (4.28%)

06/23/17
STFL
06/23/17
NO CHANGE
STFL
Fitbit reorganization of product development efforts positive, says Stifel
After meeting with Fitbit's VP, IR, Stifel analyst Jim Duffy says that the company's acquisition of software assets from Pebble and subsequent reorganization have left it better positioned to develop new products more quickly. The analyst adds that the the company is now better positioned to benefit from solutions created by third party developers. Duffy adds that checks show that the company is making progress in lowering its inventories, and he remains "encouraged" by the company's positioning in the wearables category. However, he trimmed his price target on the name to $6 from $7 and keeps a Hold rating on the stock.
07/26/17
CLVD
07/26/17
NO CHANGE
CLVD
Neutral
Fitbit estimates lowered on cautious feedback at Cleveland Research
Cleveland Research analyst Ben Bollin's checks suggest wearable sell through remains challenging, with elevated Fitbit inventory, and weakening trends, especially in Europe. The analyst lowered his Fitbit FY17 revenue estimate to reflect Surge 2 feedback of muted partner commitments and now sees sell through declines of 20%-30%. Bollin's Fitbit Q2 estimates are (17c)/$337M, versus consensus of (15c)/$341M, and he reduced FY17 estimates to (44c)/$1.54B, versus consensus of (35c)//$1.62B. Shares are Neutral rated.
07/31/17
MSCO
07/31/17
NO CHANGE
Target $6.5
MSCO
Equal Weight
Fitbit price target cut to $6.50 on sell through declines at Morgan Stanley
Morgan Stanley analyst Yuuji Anderson channel feedback and Google search analysis indicates Fitbit's overall unit sell-through year-over-year is declining, and the recently launched Alta HR is having a minimal impact. Anderson lowered FY18 estimates to reflect expectations for continued weakness in the activity tracker category into next year and cut his price target on Fitbit to $6.50 from $7.00. The analyst rates Fitbit an Equal Weight.
08/03/17
BNCH
08/03/17
NO CHANGE
Target $10
BNCH
Buy
Fitbit 'not just another broken' consumer electronics company, says Benchmark
Benchmark analyst Scott Searle noted that Fitbit announced Q2 results that were slightly ahead of expectations and importantly said its smartwatch introduction is expected in time for the holiday selling season. He views Fitbit as positioned to participate in industry growth and "not just another broken" consumer electronics company, he tells investors. Searle has a Buy rating and $10 price target on Fitbit shares.

TODAY'S FREE FLY STORIES

BSX

Boston Scientific

$38.37

0.61 (1.62%)

15:05
09/24/18
09/24
15:05
09/24/18
15:05
Options
Boston Scientific call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

SWCH

Switch

$10.83

-0.23 (-2.08%)

, INTC

Intel

$46.92

0.28 (0.60%)

15:04
09/24/18
09/24
15:04
09/24/18
15:04
Hot Stocks
Intel Capital sells about 1.728M shares of Switch »

According to a regulatory…

SWCH

Switch

$10.83

-0.23 (-2.08%)

INTC

Intel

$46.92

0.28 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 22

    Oct

MTNB

Matinas BioPharma

$0.55

0.1392 (33.98%)

, AMRN

Amarin

$11.62

8.62 (287.33%)

15:03
09/24/18
09/24
15:03
09/24/18
15:03
Recommendations
Matinas BioPharma, Amarin analyst commentary  »

Amarin's Vascepa…

MTNB

Matinas BioPharma

$0.55

0.1392 (33.98%)

AMRN

Amarin

$11.62

8.62 (287.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

15:00
09/24/18
09/24
15:00
09/24/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

KOS

Kosmos

$9.45

-0.06 (-0.63%)

14:58
09/24/18
09/24
14:58
09/24/18
14:58
Hot Stocks
Breaking Hot Stocks news story on Kosmos »

First Reserve GP XIII…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$10.76

-0.3 (-2.71%)

14:58
09/24/18
09/24
14:58
09/24/18
14:58
Conference/Events
Switch management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

CGC

Canopy Growth

$52.68

2.92 (5.87%)

, CVSI

CV Sciences

$0.00

(0.00%)

14:55
09/24/18
09/24
14:55
09/24/18
14:55
Hot Stocks
NY Governor signs bill adding pain management as condition for medical marijuana »

New York Governor Andrew…

CGC

Canopy Growth

$52.68

2.92 (5.87%)

CVSI

CV Sciences

$0.00

(0.00%)

ACBFF

Aurora Cannabis

$0.00

(0.00%)

CRON

Cronos Group

$11.80

-0.71 (-5.68%)

TLRY

Tilray

$105.00

-18.155 (-14.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

SBUX

Starbucks

$56.88

-0.52 (-0.91%)

14:50
09/24/18
09/24
14:50
09/24/18
14:50
Periodicals
Starbucks plans 'significant changes' to company structure, Bloomberg says »

Starbucks'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

RRGB

Red Robin

$38.65

-0.55 (-1.40%)

14:50
09/24/18
09/24
14:50
09/24/18
14:50
Conference/Events
Red Robin management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ASNA

Ascena Retail

$3.94

-0.29 (-6.86%)

14:49
09/24/18
09/24
14:49
09/24/18
14:49
Options
Ascena Retail options imply 24.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AMRN

Amarin

$11.13

8.13 (271.00%)

, SNY

Sanofi

$43.33

-0.28 (-0.64%)

14:48
09/24/18
09/24
14:48
09/24/18
14:48
Hot Stocks
Amarin CEO says Vascepa 'more analogous' to statins than PCSK9 inhibitors »

Amarin CEO John Thero…

AMRN

Amarin

$11.13

8.13 (271.00%)

SNY

Sanofi

$43.33

-0.28 (-0.64%)

REGN

Regeneron

$388.88

-1.67 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

TRXC

TransEnterix

$6.70

0.27 (4.20%)

14:45
09/24/18
09/24
14:45
09/24/18
14:45
Options
TransEnterix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 27

    Nov

SPPI

Spectrum

$17.18

-4.19 (-19.61%)

14:44
09/24/18
09/24
14:44
09/24/18
14:44
Hot Stocks
Spectrum drops over 20% after releasing poziotinib data from Phase 2 study »

Shares of Spectrum are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

JNJ

Johnson & Johnson

$140.67

-2.18 (-1.53%)

14:43
09/24/18
09/24
14:43
09/24/18
14:43
Periodicals
J&J talc cancer case in California ends in mistrial, Bloomberg reports »

Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

VSTM

Verastem

$8.98

0.31 (3.58%)

14:39
09/24/18
09/24
14:39
09/24/18
14:39
Hot Stocks
Verastem's Duvelisib approved by FDA »

Duvelisib capsules for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

VSTM

Verastem

$8.98

0.31 (3.58%)

14:38
09/24/18
09/24
14:38
09/24/18
14:38
Hot Stocks
Breaking Hot Stocks news story on Verastem »

Verastem trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

P

Pandora

$9.07

-0.01 (-0.11%)

14:30
09/24/18
09/24
14:30
09/24/18
14:30
Options
Heavy trading in Pandora Monday »

Heavy trading in Pandora…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GOOG

Alphabet

$1,176.08

9.87 (0.85%)

, GOOGL

Alphabet Class A

$1,183.18

10.96 (0.93%)

14:28
09/24/18
09/24
14:28
09/24/18
14:28
Periodicals
Google to bring Google Lens to Image search results, Engadget says »

According to Engadget,…

GOOG

Alphabet

$1,176.08

9.87 (0.85%)

GOOGL

Alphabet Class A

$1,183.18

10.96 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

VIAB

Viacom

$32.44

0.08 (0.25%)

14:25
09/24/18
09/24
14:25
09/24/18
14:25
Options
Viacom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
09/24/18
09/24
14:25
09/24/18
14:25
General news
FOMC begins its 2-day meeting Tuesday, with the announcement due Wednesday at 14 ET »

FOMC begins its 2-day…

ESRX

Express Scripts

$94.41

-0.2 (-0.21%)

, GILD

Gilead

$75.68

0.17 (0.23%)

14:20
09/24/18
09/24
14:20
09/24/18
14:20
Hot Stocks
Express Scripts calls Gilead action 'step in the right direction' »

Express Scripts (ESRX)…

ESRX

Express Scripts

$94.41

-0.2 (-0.21%)

GILD

Gilead

$75.68

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/24/18
09/24
14:17
09/24/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/24/18
09/24
14:16
09/24/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,177.62

11.41 (0.98%)

, GOOGL

Alphabet Class A

$1,184.38

12.16 (1.04%)

14:13
09/24/18
09/24
14:13
09/24/18
14:13
Hot Stocks
Google launches 'major update' Discover for Search »

Google said in a blog…

GOOG

Alphabet

$1,177.62

11.41 (0.98%)

GOOGL

Alphabet Class A

$1,184.38

12.16 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

14:10
09/24/18
09/24
14:10
09/24/18
14:10
General news
U.S. equities stabilized above lows after the Rosengren rout »

U.S. equities stabilized…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.